Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Regulatory News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

Share Price is delayed by 15 minutes
Get Live Data
46.00    0.00 (0.00%)
Bid:
45.00
Ask:
47.00
Spread: 2.00 (4.444%)
Market Cap: £91.78m
FARN Live PriceLast checked at - London Stock Exchange

Intraday Faron Pharmaceuticals Share Chart

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

24 Mar 2026 16:30

Faron Pharmaceuticals Ltd | Company announcement | March 24, 2026 at 18:30:00 EET

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuerx
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rightsx
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii: Dividend payments in kind.x
3. Details of person subject to the notification obligation iv
NameTimo Syrj¤l¤
City and country of registered office (if applicable)Monaco
4. Full name of shareholder(s) (if different from 3.) v
NameAcme Investments SPF Sarl
City and country of registered office (if applicable)Luxembourg
5. Date on which the threshold was crossed or reached vi:20.03.2026
6. Date on which issuer notified (DD/MM/YYYY):23.03.2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)Total of both in % (8.A + 8.B)Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached12.69%14.697.112
Position of previous notification (ifapplicable)13.90%16.093.129
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type ofsharesISIN code (if possible)Number of voting rights ix% of voting rights
Direct(DTR5.1)Indirect(DTR5.2.1)Direct(DTR5.1)Indirect(DTR5.2.1)
FI40001533095.621.0959.076.0174.85%7.84%
SUBTOTAL 8. A14.697.11212.69%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrumentExpirationdate xExercise/ Conversion Period xiNumber of voting rights that may be acquired if the instrument isexercised/converted.% of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrumentExpirationdate xExercise/ Conversion Period xiPhysical or cashSettlement xiiNumber of voting rights% of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark theapplicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xivX
Name xv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
Timo Syrj¤l¤ (Direct)4.85%4.85%
Acme Investments SPF Sarl (Indirect)7.84 %7.84 %
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
Place of completionMonaco
Date of completion23.3.2026
Date   Source Headline
27th Apr 20207:00 amRNSTraumakine to be a part of WHO’s Solidarity trial
23rd Apr 20201:00 pmRNSUpdate on results of Placing and issue of equity
22nd Apr 20207:00 amRNSResult of placing and issue price
21st Apr 20204:45 pmRNSProposed Placing
15th Apr 202011:06 amRNSSecond Price Monitoring Extn
15th Apr 202011:00 amRNSPrice Monitoring Extension
14th Apr 20207:00 amRNSNotice of Annual General Meeting
3rd Apr 20202:45 pmRNSAGM to be postponed
1st Apr 20207:00 amRNSREMAP-CAP to study IFN beta-1a effect in COVID-19
30th Mar 20207:00 amRNSPart 1 of the MATINS Phase I/II Study Completed
26th Mar 202010:00 amRNSCorrection to Faron´s Annual Report 2019
25th Mar 20207:28 amRNSFaron´s Annual Report 2019 published
20th Mar 202011:30 amRNSNotice of Annual General Meeting
20th Mar 20207:00 amRNSFinal Results for the year ended December 31, 2019
19th Mar 20204:41 pmRNSSecond Price Monitoring Extn
19th Mar 20204:36 pmRNSPrice Monitoring Extension
12th Mar 20204:44 pmRNSSecond Price Monitoring Extn
12th Mar 20204:38 pmRNSPrice Monitoring Extension
9th Mar 20207:00 amRNSFDA accepts protocol for new Traumakine trial
5th Mar 20207:00 amRNSMATINS update
2nd Mar 20207:00 amRNSFaron to acquire AOC3 antagonist platform
26th Feb 20207:05 amRNSPrice Monitoring Extension
26th Feb 20207:01 amRNSSecond Price Monitoring Extn
26th Feb 20207:00 amRNSPrice Monitoring Extension
25th Feb 20202:05 pmRNSSecond Price Monitoring Extn
25th Feb 20202:00 pmRNSPrice Monitoring Extension
25th Feb 202011:00 amRNSPrice Monitoring Extension
24th Feb 20204:41 pmRNSSecond Price Monitoring Extn
24th Feb 20204:35 pmRNSPrice Monitoring Extension
18th Feb 202011:06 amRNSSecond Price Monitoring Extn
18th Feb 202011:00 amRNSPrice Monitoring Extension
18th Feb 20209:05 amRNSSecond Price Monitoring Extn
18th Feb 20209:00 amRNSPrice Monitoring Extension
6th Feb 20207:00 amRNSTraumakine update
27th Jan 20207:00 amRNSOvarian cancer selected as 2nd MATINS trial cohort
13th Jan 20207:00 amRNSDMC approves colorectal cancer cohort expansion
30th Dec 20199:30 amRNSUpdate on Traumakine drug substance manufacturing
12th Dec 20192:00 pmRNSPrice Monitoring Extension
11th Dec 20197:00 amRNSMatins Trial Update
2nd Dec 20192:06 pmRNSSecond Price Monitoring Extn
2nd Dec 20192:00 pmRNSPrice Monitoring Extension
29th Nov 20192:05 pmRNSSecond Price Monitoring Extn
29th Nov 20192:00 pmRNSPrice Monitoring Extension
29th Nov 20197:31 amRNSLIQUIDITY PROVIDING AGREEMENT
29th Nov 20197:30 amRNSCompany Description & information on cash position
28th Nov 20199:05 amRNSSecond Price Monitoring Extn
28th Nov 20199:00 amRNSPrice Monitoring Extension
28th Nov 20197:00 amRNSFDA has approved Faron's Clevegen IND
27th Nov 20194:00 pmRNSFaron´s financial calendar for 2020
21st Nov 20192:00 pmRNSHoldings in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.